Texere SA
Ouverture de faillite 5.1 FTETexere reported total assets of €2.24m at the end of the 2025 financial year (annual accounts filed with the NBB on 25 Jun 2026), with 5.1 full-time equivalents.
The score of Texere shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Texere's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 25 Jun 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
Texere's financial analysis
- Solvency-26.0%sector median: 66.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Texere
Texere's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1005.576.333
- VAT number
- BE1005576333
- Peppol
- Registered · 9925:be1005576333 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 02 Feb 2024
- Registered office
- 6210 Les Bons Villers
- Size
- Micro · 5.1 FTE
- Latest accounts
- 2025 · filed on 25 Jun 2026
- Activity
- Diagnostic imaging services and medical laboratory activities (NACE 86910)
Texere (SA) has been based in Les Bons Villers since 2024, active in: diagnostic imaging services and medical laboratory activities. For 2025, it reports a net loss of €1.10m and equity of −583,912 €; its revenue is not published. With 5.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -26.0%, below the median of its sector (66.2%).
Companies similar to Texere
Companies in the same business, of comparable size and area, outside its group.
- InnoSer België Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet €2.12m
- Aligos Belgium Research and experimental development on natural sciences and engineering Leuven · balance sheet €1.82m
- Dr. Timothy Boussy Diagnostic imaging services and medical laboratory activities Sint-Martens-Latem · balance sheet €1.45m
- E.H.D. BIO Diagnostic imaging services and medical laboratory activities Hannut · balance sheet €1.36m
- Apr. Biol. Inger Brandt Research and experimental development on natural sciences and engineering Lebbeke · balance sheet €2.44m
- BIO.BE Diagnostic imaging services and medical laboratory activities Charleroi · balance sheet €3.04m
- Fertiga Research and experimental development on natural sciences and engineering Lede · balance sheet €2.06m
- care2trans Research and experimental development on natural sciences and engineering Merelbeke-Melle · balance sheet 817,653 €
Frequently asked questions about Texere
What is the revenue of Texere?
Texere files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Texere?
In Belgium, the VAT number is the company number prefixed with BE: BE1005576333 for Texere, if the company is VAT-registered. Its company number (CBE) is 1005.576.333.
Where is the registered office of Texere?
According to the CBE register, the registered office of Texere is in 6210 Les Bons Villers.
What is the equity of Texere?
At the close of the 2025 financial year, the equity of Texere amounts to -583,912 €, a solvency of -26.0% of total assets.
How many people work at Texere?
5.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Texere?
The register lists 3 active mandates at Texere. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Texere
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →